Hydroxyethyl starch 200/0.5 is supplied as a pharmaceutical-grade semisynthetic amylopectin derivative in which the hydroxyl groups at the C2 and C6 positions of anhydroglucose units are partially substituted with hydroxyethyl groups. The model designation HES 200/0.5 encodes a nominal weight-average molecular weight of 200,000 Da and a molar substitution of 0.5. The product line includes HES 200/0.5 and co-supplied active pharmaceutical ingredients released for tablet, capsule, granule, injection, oral, and injectable dosage forms. Hydroxyethylation alters enzymatic recognition by α-amylase; the resulting polymer is not a simple native starch, and its colloid osmotic activity in solution is governed by molecular weight distribution, molar substitution, and the C2/C6 substitution ratio. Manufacturing documentation follows ICH Q7 for active pharmaceutical ingredients; injectable lots require endotoxin, bioburden, residual solvent, and molecular weight distribution data before release.

The pharma-grade designation means that each batch is released against a certificate of analysis containing chemical, physical, microbiological, and residue test results. The packaging configuration is selected according to route: injectable-grade material is supplied in double polyethylene bags inside sealed fibre drums; solid oral material may be supplied in LDPE-lined drums. Cross-contamination control follows 21 CFR 211 for finished pharmaceuticals and ICH Q7 for APIs.

The polymer is produced from waxy maize starch by controlled acid hydrolysis, followed by hydroxyethylation with ethylene oxide under alkaline conditions. The hydrolysis step sets the molecular weight target, while the hydroxyethylation step introduces short hydroxyethyl chains at the reactive hydroxyl positions. Residual ethylene oxide and ethylene chlorohydrin are controlled as process residues. The crude product is purified by precipitation or diafiltration and dried to a loss-on-drying specification of ≤5.0%. The resulting powder is white to off-white and freely soluble in water; solubility and clarity are monitored in release testing because incomplete purification can leave insoluble amylopectin aggregates that increase subvisible particulate counts in injectable formulations.

Molecular weight and molar substitution are not independent variables: a higher molar substitution at a given molecular weight will reduce the rate of α-amylase hydrolysis. For this reason, the 0.5 molar substitution represents a deliberate balance between intravascular persistence and tissue clearance. In solid dosage forms, the same balance affects dissolution and tablet disintegration because water penetration is faster through unsubstituted starch regions.

Which Specification Limits Govern Injectable-Grade HES 200/0.5?

Release testing for injectable HES 200/0.5 starts with molecular weight distribution by size-exclusion chromatography coupled to multi-angle laser light scattering, using Ph. Eur. 2.2.30 as the system suitability reference. The nominal 200,000 Da weight-average molecular weight is not a single-chain mass but a distribution; control of the Mw/Mn ratio is necessary because high-molecular-weight fractions above 220,000 Da can increase solution viscosity and prolong renal retention. Molar substitution is determined after acid hydrolysis by gas chromatography, with an acceptance window of 0.45–0.55. The C2/C6 substitution ratio is measured by GC or NMR; published data for this specific configuration is limited, but a higher C2 substitution is understood to confer greater α-amylase resistance than C6 substitution. Residual ethylene oxide is controlled under Ph. Eur. 2.4.25 and ICH Q3C; bacterial endotoxin is measured by Ph. Eur. 2.6.14 with a typical parenteral limit of ≤0.5 EU/mg. Elemental impurities are controlled by ICH Q3D using ICP-MS.

Water content is critical because HES 200/0.5 is amorphous and hygroscopic. Loss on drying above 5.0% may not indicate degradation, but it alters powder flow and can increase the risk of sticking to tooling. Moisture-corrected assay is performed by deducting loss on drying from the active assay result to prevent overestimation of potency.

In high-shear wet granulation, HES 200/0.5 is introduced as an aqueous binder solution at 5–10% w/w. The solution is sprayed onto a lactose-monohydrate and microcrystalline cellulose blend in a high-shear mixer with impeller tip speed between 4 and 8 m/s; granulation end point is controlled by torque rise rather than fixed time. Over-wetting produces agglomerates above 2 mm and increases fluid-bed drying at 60 °C beyond 40 min, which can lower tablet hardness through case hardening. Dried granules are milled through a 0.8 mm screen and blended with 0.5% w/w magnesium stearate; tablet hardness is maintained between 60 and 100 N for 10 mm round tooling. Capsule filling requires loss on drying below 5.0% because the amorphous starch derivative is hygroscopic and will plasticise gelatin or HPMC shells at RH > 60%. Injectable manufacturing dissolves HES 200/0.5 in water for injection and terminally steam-sterilises at 121 °C for 15 min; the cycle must be re-validated by SEC because autoclaving can shift the molecular weight distribution. Co-supplied APIs in the same pharma-grade line are released separately under ICH Q7 and cannot be treated as interchangeable without route-specific specifications.

Oral solid dosage forms use HES 200/0.5 in wet granulation at 2–5% w/w of the dry formulation as a binder. For extended-release matrices, higher levels up to 10% w/w are used with hypromellose or ethylcellulose to modify drug release. In capsule filling, granules are milled and filled by tamping or dosator systems; fill weight is adjusted to control weight variation under USP <905>, and moisture is kept below 5.0% to avoid shell deformation. For oral granules, the material is dry-mixed or wet-granulated and then passed through a 0.5–1.0 mm sieve; final blend uniformity is verified by pharmacopoeial sampling. Binding performance is not determined solely by molecular weight. The 0.5 molar substitution leaves sufficient unsubstituted regions for water uptake and film formation, while substituted regions suppress rapid enzymatic breakdown. In tablet formulations containing hygroscopic drugs, the binder solution is prepared at 25 °C and used within 8 h to avoid microbial proliferation. If the granulation is stored before compression, it should be held in sealed containers at RH < 40% to prevent moisture migration and the resulting loss of tablet hardness.

The use of HES 200/0.5 as a granulation binder does not automatically confer extended-release behaviour; drug release rate is governed by matrix polymer ratio, drug solubility, and compression force. A formulation with 10% w/w binder and a freely soluble drug may still release more than 80% of drug in 30 min under USP dissolution; therefore, dissolution testing should be used to confirm the desired profile.

Solid Oral Versus Injectable Processing Cannot Be Treated as Equivalent

The same HES 200/0.5 grade can be referenced for tablet and injection manufacturing, but the control envelopes differ by route. Solid oral use permits a wider bioburden envelope but requires powder flow and particle-size control to meet USP <905> uniformity of dosage units; injectable use demands bacterial endotoxin control, terminal sterilisation compatibility, and subvisible particulate limits under Ph. Eur. 2.9.19 or USP <788>. A lot released for oral granulation is not automatically suitable for parenteral compounding unless the batch meets the parenteral specification for endotoxin, bioburden, and residual solvent. For injectable filling, the solution is processed in an ISO 7 cleanroom with ISO 5 laminar airflow at the point of fill; terminal sterilisation by moist heat is validated according to Ph. Eur. 5.1.1. The presence of other active pharmaceutical ingredients in the product line does not imply pre-mixed formulation; each API is supplied with its own certificate of analysis and route-specific documentation.

When Hydroxyethyl Starch Replaces Pregelatinised Starch in Wet Granulation

The substitution pattern changes binder performance. Pregelatinised starch hydrates rapidly without cooking but is more sensitive to α-amylase and can swell unevenly when the granulation fluid is added too quickly. HES 200/0.5 in aqueous solution gives a more shear-thinning binder; its 0.5 molar substitution reduces the thickness of the hydrated layer compared with HES 200/0.62 and permits easier spray application. However, the same shear-thinning behaviour means nozzle clogging can occur if the solution is allowed to cool and viscosity rises; jacketed spray lines at 25–30 °C are recommended. Batch-to-batch variation in molecular weight distribution changes solution viscosity more than granule particle size; therefore, binder solution viscosity should be checked by Ph. Eur. 2.2.10 before spraying, and the addition rate adjusted to avoid a wet mass that forms ropes or sticks to the bowl wall.

Dry HES 200/0.5 is sensitive to moisture. Storage in sealed polyethylene-lined fibre drums below 25 °C and RH < 60% is specified; opened containers should be re-sealed immediately. At RH > 60%, moisture uptake plasticises the amorphous starch matrix and can increase particle adhesion during tableting. The product is incompatible with strong oxidising agents; compatibility with cationic APIs should be confirmed on a case-by-case basis because residual anionic groups can cause complex formation in solution. For injectable admixtures, electrolytes such as calcium chloride or high-phosphate buffers may alter the zeta potential and should be tested for precipitation before batch manufacture.

Injectable solutions of HES 200/0.5 generate colloid osmotic pressure because the high-molecular-weight fraction is retained within the vascular compartment. A 6% w/v solution generates a colloid osmotic pressure determined by the concentration and the molecular weight distribution; routine release data include SEC traces to confirm that the high-molecular-weight fraction is present. α-Amylase degradation assays are used to compare relative degradation rates: HES 200/0.5 degrades more slowly than HES 130/0.4 and more quickly than HES 200/0.62 under the same enzyme activities. The degradation products are cleared by renal and hepatic routes; this is why renal function monitoring is required. Regional regulatory restrictions apply to hydroxyethyl starch solutions; manufacturers must verify current label indications before formulation.

For injectable products, HES 200/0.5 is commonly formulated at 6% w/v in 0.9% w/v sodium chloride. The solution is filtered through 0.2 µm sterilising-grade filters before terminal sterilisation. Autoclaving at 121 °C for 15 min can decrease the weight-average molecular weight; therefore, SEC is repeated post-sterilisation to confirm that the molecular weight distribution remains within specification. Subvisible particulate testing according to USP <788> or Ph. Eur. 2.9.19 is required for injectable formulations; the acceptance criterion for particles ≥ 10 µm and ≥ 25 µm follows compendial limits. The product must not be combined with amine-containing APIs that can react with residual reducing end groups; such combinations require forced degradation studies to confirm absence of Maillard-type adducts.

Compared with HES 130/0.4, HES 200/0.5 exhibits a higher weight-average molecular weight and a higher molar substitution, which jointly reduce enzymatic hydrolysis and prolong intravascular retention. Compared with HES 200/0.62, the 0.5 molar substitution leaves fewer hydroxyethyl blocking groups, allowing faster α-amylase degradation and lower tissue accumulation. Compared with HES 450/0.7, HES 200/0.5 has a shorter circulating persistence and a lower tissue storage risk; however, all hydroxyethyl starch products require dose limitation and renal function monitoring in clinical use. In solid oral formulations, native starch, pregelatinised starch, and sodium starch glycolate are not interchangeable with HES 200/0.5: native starch has limited cold-water solubility, pregelatinised starch swells but lacks the same substituted amylase resistance, and sodium starch glycolate functions as a disintegrant rather than a binder or colloid. HES 200/0.5 is therefore selected when water-soluble binding, matrix formation, or colloid osmotic activity is required.

From a release perspective, oral and injectable versions are differentiated by the route-specific acceptance values for endotoxin, bioburden, and particulates, not by the HES grade name alone. A tablet binder lot may meet chemical identity and molar substitution but still fail injectable endotoxin testing; therefore, the intended manufacturing route must be fixed before lot selection.